AstraZeneca to Invest US$4.5 Billion to Expand Manufacturing Facility in Virginia
Introduction:
AstraZeneca has announced plans to invest US$4.5 billion to expand its manufacturing facility at Rivanna Futures in Albemarle County, Virginia.
Features:
The Virginia facility is designed to strengthen domestic pharmaceutical manufacturing capabilities and support production of a wide range of therapeutic products, including small molecule medicines and antibody-drug conjugates (ADCs).
Advanced manufacturing technologies will be integrated throughout the site, including automation, digital process monitoring, and data analytics to enhance efficiency, consistency, and process control.
Operations will cover end-to-end production, from raw material processing to drug substance synthesis, formulation, and packaging, enabling streamlined workflows across multiple product lines.
Production will include medicines from metabolic, oncology, and other therapeutic portfolios, ensuring flexibility to accommodate future pipeline developments.
Sustainability and resource efficiency are key considerations in the facility’s design, incorporating energy-optimised systems, waste minimisation measures, and environmentally responsible practices.
The layout allows modular and flexible manufacturing, supporting multiple product types simultaneously while reducing cross-contamination risks.
Digital tools and process analytical technologies will enable real-time monitoring, predictive maintenance, and quality assurance throughout production, helping maintain high standards of consistency and reliability.
The expanded site reflects modern trends in pharmaceutical manufacturing towards advanced, flexible, and sustainable facilities capable of supporting evolving healthcare needs and complex biologic and small molecule therapies.
Specifications:
| Name | AstraZeneca |
| Type | New Construction |
| Budget | US$4.5 billion |
| Year | TBA |
